(Q48567066)

12 February 2018

title

Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. (English)

1 reference

12 February 2018

0 references

1 reference

10

Jedd D Wolchok

1 reference

12 February 2018

Katherine S Panageas

2

object named as

Katherine S Panageas

1 reference

12 February 2018

author name string

Wen-Jen Hwu

1

1 reference

12 February 2018

Jennifer H Menell

3

1 reference

12 February 2018

Lynne A Lamb

4

1 reference

12 February 2018

Suzan Aird

5

1 reference

12 February 2018

Susan E Krown

6

1 reference

12 February 2018

Linda J Williams

7

1 reference

12 February 2018

Paul B Chapman

8

1 reference

12 February 2018

Philip O Livingston

9

1 reference

12 February 2018

Alan N Houghton

11

1 reference

12 February 2018

language of work or name

English

0 references

publication date

1 June 2006

1 reference

12 February 2018

published in

Cancer

1 reference

12 February 2018

volume

106

1 reference

12 February 2018

issue

11

1 reference

12 February 2018

page(s)

2445-2451

1 reference

12 February 2018

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Management of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Temozolomide: a novel oral alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Analysis of survival by tumor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

inferred from DOI database lookup

7 January 2021

based on heuristic

Interferons in the treatment of malignant melanoma. A review of recent trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21909

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.21909

1 reference

12 February 2018

1 reference

12 February 2018